This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Expert Interviews in Dyslipidemia and Atherosclerosis - 2018 CMHC West Virtual Highlights

Expert Interviews in Dyslipidemia and Atherosclerosis - 2018 CMHC West Virtual Highlights

Format

Webcast

Time to Complete

2 hours

Released

July 31, 2018

Expires

July 31, 2019
Add to Queue


Maximum Credits

2.00 / AMA PRA Category 1 CreditsTM
2.00 / CNE for Nurses
2.00 / CE for Pharmacists (0.20 CEUs)
2.00 / CPEU for Registered Dietitians

Accredited Provider

This activity is jointly provided by Global Education Group and Tarsus Cardio Inc. dba Cardiometabolic Health Congress.

Commercial Supporter

This activity is supported by educational funding provided by Amgen.

Program Description

This educational activity is comprised of a collection of 4 expert commentary interviews that highlight the most pertinent content from the Dyslipidemia/Atherosclerosis Session at the 2018 CMHC West meeting. As heart disease is the leading cause of death in the Unites States, healthcare providers can play a major role in stemming the future burden of cardiovascular disease by employing strategies for the early identification and comprehensive management of patients presenting with multiple cardiometabolic risk factors. The following 4 modules will equip healthcare providers with the knowledge necessary to address these clinical challenges:

  • Module 1: Triglycerides and Cardiovascular Disease
  • Module 2: Familial Hypercholesterolemia: Identification and Management
  • Module 3: Importance of Lifestyle Modifications and Incorporation into Clinical Practice
  • Module 4: Non-Statin Drugs and New Approaches
Downloadable transcripts and slides will also be provided to learners.

Intended Audience

US-based healthcare professionals, including primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, and other allied health professionals

Educational Objectives

Upon completion of this activity, participants should be able to:

  • Identify appropriate lipid management strategies for patients at high risk of ASCVD
  • Describe the efficacy and safety of current and emerging agents for dyslipidemia
  • Review the latest published guidelines and recommendations for lipid management, including pharmacotherapy and lifestyle modifications

Conflict Of Interest Disclosure Policy

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Faculty

Christie M. Ballantyne, MD (Chair)
Professor of Medicine
Chief, Section of Cardiovascular Research
Chief, Section of Cardiology
Department of Medicine, Baylor College of Medicine
Director, Center for Cardiovascular Disease Prevention
Baylor College of Medicine
Methodist DeBakey Heart Center
Houston, TX

Dr. Ballantyne discloses the following:
Grant/Research Support (all significant, all paid to institution, not individual): Abbott Diagnostic, Amarin, Amgen, Esperion, lonis, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi Synthelabo, NIH, AHA, ADA
Consultant/Independent Contractor: Abbott Diagnostics, Amarin, Amgen, AstraZeneca*, Boehringer lngelheim*, Eli Lilly, Esperion, lonis, Matinas BioPharma Inc, Merck*, Novartis, Pfizer*, Regeneron, Roche Diagnostic, Sanofi-Synthelabo*
*Significant where noted (>$10,000); remainder modest (<$10,000)>

Alan Chait, MD
Edwin L. Bierman Professor of Medicine
Division of Metabolism, Endocrinology & Nutrition
University of Washington
Seattle, WA

Dr. Chait has nothing to disclose.

Robert H. Eckel, MD (Chair)
Professor of Medicine
Division of Endocrinology, Metabolism and Diabetes
Division of Cardiology
Professor of Physiology and Biophysics
Charles A. Boettcher II Chair in Atherosclerosis
Director, T32 in Obesity and Cardiovascular Disease
University of Colorado Anschutz Medical Campus
Director, Lipid Clinic, University Hospital
Aurora, CO

Dr. Eckel discloses the following:
Consultant/Independent Contractor: Sanofi/Regeneron, Novo Nordisk

Nancy Houston Miller, RN, BSN
Clinical Assistant Professor, Johns Hopkins School of Nursing, Baltimore, Maryland
Co-director, The LifeCare Company
Menlo Park, CA

Ms. Miller discloses the following:
Consultant/Independent Contractor: Moving Analytics Inc
Speakers Bureau: Practice Point Stables Ischemic Heart Disease

Joshua W. Knowles, MD
Assistant Professor of Cardiovascular Medicine
Stanford University Medical Center
Stanford, CA

Dr. Knowles discloses the following:
Grant/Research Support: Amgen, AHA

Marc S. Sabatine, MD, MPH
Chairman, TIMI Study Group
Lewis Dexter, MD Distinguished Chair in Cardiovascular Medicine
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, MA

Dr. Sabatine discloses the following:
Consultant/Independent Contractor: Amgen; Bristol-Myers Squibb; CVS Caremark; Esperion; Ionis; Intarcia; Janssen Research and Development; MedImmune; Merck; Novartis (all ≤$10,000 per year except Amgen and Esperion)
Grant/Research Support: Amgen; AstraZeneca; Daiichi-Sankyo; Eisai; GlaxoSmithKline; Intarcia; Janssen Research and Development; Medicines Company; MedImmune; Merck; Novartis; Pfizer; Poxel; Takeda

Sotirios Tsimikas, MD
Professor of Medicine
Director of Vascular Medicine
University of California San Diego
La Jolla, CA

Dr. Tsimikas discloses the following:
Consultant/Independent Contractor: UCSD
Grant/Research Support: Regeneron, Amgen
Stock Shareholder: Ionis
Other/Royalty: UCSD patents

Karol E. Watson, MD, PhD, FACC
Professor of Medicine/Cardiology
Co-director, UCLA Program in Preventive Cardiology
Director, UCLA Barbra Streisand
Women’s Heart Health Program
UCLA
Redondo Beach, CA

Dr. Watson discloses the following:
Consultant/Independent Contractor: Amgen, Boehringer Ingelheim, Amarin
Grant/Research Support: NIH
Speakers Bureau: Boehringer Ingelheim

Accredited Provider Disclosure

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN, has nothing to disclose.
Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Amanda Turner has nothing to disclose.
Erin Franceschini, MS, has nothing to disclose.
Karin McAdams has nothing to disclose.

Credit

2.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and CMHC. Global is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Global Education Group designates this virtual activity for a maximum of 2.00 AMA PRA Category 1 CreditsTM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

2.00

Type

CNE Contact Hour(s)

Accreditation Statement

Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation Statement

This educational activity for 2.00 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Credit

2.00

Type

CE for Pharmacists

Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation Statement

Global Education Group designates this continuing education activity for 2.00 contact hour(s) (0.20 CEUs) of the Accreditation Council for Pharmacy Education. This is a knowledge based activity.

Universal Activity Number (UAN): 0530-9999-18-198-H01-P

Credit

2.00

Type

CPEU Credit

Accreditation Statement

Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR).

Designation Statement

CDR Credentialed Practitioners will receive 2.00 Continuing Professional Education units (CPEUs) for completion of this activities / materials.

CPE Provider #GE012

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and CMHC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed all 4 modules, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For information about the accreditation of this activity, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.

If you have any other questions relating to your certificate or other issues with the activity, please contact myCME.Support@haymarketmedical.com.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue